Safety & Efficacy of Extended Longevity Protocol

The Safety and Effectiveness of the Extended Longevity Protocol on the Epigenetic Aging Rate in Healthy Individuals

The purpose of this study is to quantifiably determine if the Extended Longevity Protocol has a significant clinical effect on epigenetic age.

This is a prospective non-randomized clinical study of 15 patients to determine if the safety and effectiveness of the Extended Longevity Protocol's impact on the nine determinant factors of aging can decelerate aging.

There is evidence that the Extended Longevity Protocol decelerates aging and the risk of age-related diseases. The aim of this pilot study is to evaluate the safety, efficacy and feasibility of the Extended Longevity Protocol as an effective treatment option to improve clinical care of healthy individual's biological age thus prolonging longevity.

Inclusion Criteria:

• 8 Men and 7 Women
• Must between 55-75 years old
• Patient must be able to comply with treatment plan and laboratory tests
• Patients must have adequate immune system function, with no known immunodeficiency disease

Exclusion Criteria:

• Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
• No immune system issues or immunodeficiency disease
• No history of viral illness which could be reactivated by immune downregulation
• Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) disease
• Diagnosis of a transient ischemic attack in the 6 months prior to screening
• Patients infected with hepatitis, C or HIV
• Patients with Body Mass Index (BMI) > 40 kg/m2
• Presence of active infection
• Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study
• Unable or unwilling to provide required blood sample for testing